Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072462 | 0.94 | KDM4E (0.41) | KDM4ELMNACYP1A2CYP3A4TP53 | |
| SCHEMBL6072319 | 0.93 | HTT (0.36) | KDM4ELMNATP53POLBALDH1A1 | |
| SCHEMBL6072110 | 0.92 | CASP1 (0.35) | LMNAPKMPOLBALDH1A1MAPT | |
| SCHEMBL6072017 | 0.90 | KDM4E (0.44) | KDM4ELMNACYP1A2CYP3A4TP53 | |
| SCHEMBL6071922 | 0.90 | KDM4E (0.43) | KDM4ELMNACYP1A2CYP3A4TP53 | |
| SCHEMBL6072241 | 0.89 | MAPT (0.38) | KDM4ELMNATP53MAPTGAA | |
| SCHEMBL6072342 | 0.87 | HDAC1 (0.37) | KDM4ETP53POLBALDH1A1HDAC1 | |
| SCHEMBL6072290 | 0.85 | PPID (0.36) | LMNAPOLBALDH1A1MAPTMEN1 | |
| SCHEMBL6072367 | 0.84 | HDAC1 (0.39) | KDM4ETP53POLBALDH1A1HDAC1 | |
| SCHEMBL6071593 | 0.84 | ALDH1A1 (0.34) | KDM4ETP53PKMPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | KDM4E 358/4885LMNA 2455/4885CYP1A2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.